

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

1 - 7 June 2026



Agriculture Drives Global Ammonium Sulfate Market

A report by *Chemical & Materials* shows the global ammonium sulfate market reached \$4.5 billion in 2025. Agriculture remains the core driver, consuming 72% of total demand. Granular ammonium sulfate has become the preferred choice with a 52% market share, heavily favored for its excellent compatibility with large-scale mechanized farming and industrial storage. **(ChemNet)**

Chinese Fluoropolymer Prices Surge in June

Effective June 1, 2026, Chinese manufacturers raised factory prices for all fluoropolymers due to rising raw material and logistics costs. PTFE and FEP prices increased by 5%. Lithium-battery grade PVDF rose 5%, while coating grades climbed 10%. Fluororubber recorded the highest spike, increasing by up to 15% or a flat \$1.38/kg. **(ChemNet)**

China Salt Chemical Starts \$3.49B Soda Ash Project

China Salt Chemical announced that its \$3.49 billion natural soda ash project in Inner Mongolia officially starts construction in June 2026. The site features a 5-million-ton annual soda ash equivalent capacity and a 200,000-ton baking soda line. Technical preparations are finalized following successful mining tests in April 2026 and securing 1.447 billion tons of mining rights in 2025. **(ChemNet)**

China approves first domestic CAR-T therapy for solid tumors

China has conditionally approved the first domestically developed CAR-T cell therapy for an advanced solid tumor. Developed by a Shanghai-based firm, it marks a major advance beyond current blood cancer CAR-T treatments. Analysts say this could position China as a next-generation cell therapy contender, pending further trial data. **(National Medical Products Administration)**

China issues draft guidelines to speed up biosimilar approvals

China has released draft guidelines to streamline the development and review process for biosimilars. The new rules clarify clinical data requirements and may shorten approval timelines if strong similarity is demonstrated. The move aims to boost competition, lower drug costs, and align China with international regulatory standards. The guidelines are open for public comment. **(National Medical Products Administration)**